Table 2 Distributions of baseline variables by treatment arm, according to prognostic CLIP subgroups
From: Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma
Clip category | 0–1 | 2–6 or unknown | ||
|---|---|---|---|---|
Tamoxifen (n = 85) | Control (n = 94) | Tamoxifen (n = 152) | Control (n = 146) | |
Median (range) age (years) | 66 (37–91) | 66 (31–80) | 65 (39–86) | 67 (42–84) |
Men | 57 (67.1) | 68 (72.3) | 112 (73.7) | 115 (78.8) |
Evidence of disease at entry | 77 (90.6) | 86 (91.5) | 141 (92.8) | 137 (93.8) |
Interval between diagnosis and entry | ||||
0–6 months | 85 (100.0) | 94 (100.0) | 109 (71.7) | 105 (71.9) |
7–12 months | 0 (0.0) | 0 (0.0) | 21 (13.8) | 19 (13.0) |
13–24 months | 0 (0.0) | 0 (0.0) | 22 (14.5) | 22 (15.1) |
Child-Pugh category | ||||
A | 62 (72.9) | 67 (71.3) | 53 (34.9) | 51 (34.9) |
B | 23 (27.1) | 27 (28.7) | 72 (47.4) | 59 (40.4) |
C | 0 (0.0) | 0 (0.0) | 26 (42.6) | 35 (24.0) |
unknown | 0 (0.0) | 0 (0.0) | 1 (0.7) | 1 (0.7) |
Locoregional treatment | ||||
Surgery | 10 (11.8) | 10 (10.6) | 8 (5.3) | 5 (3.4) |
Percutaneous Ethanol Injection | 34 (40.0) | 46 (48.9) | 30 (19.7) | 32 (21.9) |
Transarterial chemoembolization | 18 (21.2) | 17 (18.1) | 24 (15.8) | 21 (14.4) |
none | 23 (27.1) | 21 (22.3) | 90 (59.2) | 88 (60.3) |